$2.63
0.77% yesterday
Nasdaq, Apr 28, 10:19 pm CET
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

ImmunityBio Inc Stock price

$2.63
-0.51 16.24% 1M
-3.54 57.37% 6M
+0.07 2.73% YTD
-6.36 70.75% 1Y
-1.11 29.68% 3Y
-0.94 26.33% 5Y
-32.01 92.41% 10Y
Nasdaq, Closing price Mon, Apr 28 2025
+0.02 0.77%
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

Key metrics

Market capitalization $2.32b
Enterprise Value $2.96b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 200.80
P/S ratio (TTM) P/S ratio 157.35
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 2,270.58%
Revenue (TTM) Revenue $14.75m
EBIT (operating result TTM) EBIT $-344.18m
Free Cash Flow (TTM) Free Cash Flow $-398.12m
Cash position $149.81m
EPS (TTM) EPS $-0.63
P/E forward negative
P/S forward 23.63
EV/Sales forward 30.16
Short interest 19.35%
Show more

Is ImmunityBio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

ImmunityBio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a ImmunityBio Inc forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a ImmunityBio Inc forecast:

Buy
80%
Hold
20%

Financial data from ImmunityBio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
15 15
2,279% 2,279%
100%
- Direct Costs 18 18
19% 19%
119%
-2.81 -2.81
87% 87%
-19%
- Selling and Administrative Expenses 136 136
54% 54%
920%
- Research and Development Expense 188 188
18% 18%
1,276%
-327 -327
4% 4%
-2,214%
- Depreciation and Amortization 18 18
19% 19%
119%
EBIT (Operating Income) EBIT -344 -344
5% 5%
-2,333%
Net Profit -414 -414
29% 29%
-2,804%

In millions USD.

Don't miss a Thing! We will send you all news about ImmunityBio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ImmunityBio Inc Stock News

Neutral
Business Wire
one day ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced positive long-term results from its QUILT-3.032 study of ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or with...
Neutral
Business Wire
8 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) and updated data on papillary disease without CIS at the American Urological Association Annual Meeting (AUA 2025) in Las Vegas, April 26-2...
Neutral
Business Wire
14 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary disease and an EAP for ANKTIVA® (nogapendekin alfa inbakicept-pmln) for the treatment of lymphopenia. Supplemental Biologics License Application (sBLA): In Q1, Immu...
More ImmunityBio Inc News

Company Profile

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Head office United States
CEO Richard Adcock
Employees 680
Founded 2014
Website www.immunitybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today